1. Background {#sec1}
=============

According to the Global Cancer Observatory, worldwide incidence was 2.09 million cases in 2018. It is also responsible of 1.76 million deaths per year. Lung cancer represents 11.6% of all malignant tumor incidence and makes 18.4% of mortality of all cancers. It has so, the highest mortality rate in men and the second-highest mortality rate in women \[[@B1], [@B2]\]. In Tunisia, tobacco smoking is still rising. Lung cancer incidence in men is 63.5 cases/100000 in the period 2004-2006. Incidence in women is 5.1 cases/100000 \[[@B3]\]. Diagnosis announcement is followed therefore by a psychological impact with variable intensity and various manifestations. Chemotherapy is proposed in stage IV of the disease if there are no contraindications. Its impact on the general status, quality of life, and sleep quality is scarcely reported \[[@B4]--[@B6]\]. These interactions between burdensome therapeutic protocols and quality of life or sleep were reported in other cancer types \[[@B7]--[@B9]\]. Preservation of sleep quality is a major palliative care goal increasingly mentioned in advanced cancer management. Nevertheless, sleep quality deterioration before and after chemotherapy has not been studied. The aim of this study was to report various sleep disturbances in advanced-stage lung cancer patients and their outcome after chemotherapy and/or radiotherapy. We aimed also to assess the correlation between sleep quality and quality of life.

2. Methods {#sec2}
==========

2.1. Design {#sec2.1}
-----------

This was a single-arm prospective cohort study conducted in the pulmonology department Pavilion 4 in Ariana Hospital, Tunisia. The follow-up period was the duration of the chemotherapy course.

2.2. Patients {#sec2.2}
-------------

We included all NSCLC patients in stage III to IV of the disease according to the 8th edition of TNM classification \[[@B10]\].

*Inclusion criteria* were confirmed NSCLC with histological proof, stage III or IV of the disease, prescription of a chemotherapy course, written informed consent to receive chemotherapy course, and written informed consent to participate in the study.

*Noninclusion criteria* were known sleep disturbance prior to lung cancer diagnosis, pharmacological treatment interfering with sleep quality, severe pain with intensity greater than 6/10 in visual analogical scale (VAS), and leading to the prescription of oral opioïd therapy.

*Exclusion criteria* were the death of the patient during the chemotherapy course, worsening of the general status leading to a medical decision to stop the chemotherapy, nonadherence of the patient to chemotherapy whatever was the reason, withdrawal of consent to participate in the study, and starting a prescription of any treatment interfering with sleep quality: morphine, neuroleptic, or antiepileptic treatment.

2.3. Methods and Assessment Tools {#sec2.3}
---------------------------------

The inclusion period lasted from February to August 2018. We included consenting patients who fulfilled the inclusion criteria. After announcing the diagnosis and the prognosis of the disease, we planned an appointment with the patient before starting the chemotherapy protocol. In this meeting, we made our first evaluation via questionnaires of the quality of life and sleep quality. We gathered also sociodemographic and clinical data. After the chemotherapy course, if there were no exclusion criteria, a second evaluation with the same methods was done. Side effects of chemotherapy administration were classified as mentioned in the "Common Terminology Criteria for Adverse Events" \[[@B11]\].

### 2.3.1. Sleep Quality Assessment {#sec2.3.1}

Pittsburgh Sleep Quality Index (PSQI) was used. It contains nineteen questions about seven dimensions of sleep disturbance patterns: global subjective quality of sleep---sleep latency---sleep duration---sleeping efficiency---sleep and wake disturbances---use of sleep medication---daytime dysfunction or sleepiness \[[@B12]\]. Every dimension is evaluated from 0 to 3 according to the patient\'s answers. The score reflects the disturbance severity. The seven dimensions scores were combined to give a global score ranging from 0 to 21, with greater scores indicating poorer sleep quality. When the PSQI score is greater than 5, sleep quality is considered as poor. The PSQI was validated for cancer patients \[[@B13]\]. We used an Arabic Tunisian dialectal version of PSQI, which is not validated yet, to be easily answered by patients (Appendix 1--Appendix 2).

### 2.3.2. Health-Related Quality of Life Assessment {#sec2.3.2}

We used the QLQ-C30 questionnaire, elaborated by the European organization of research and treatment of cancer \[[@B14]--[@B19]\]. The questionnaire included thirty forced-choice questions (Appendix 3--Appendix 4), classified as follows: Symptom items (9 items, 13 questions): fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficultiesFunctional items (5 items, 15 questions): physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioningGlobal health item (1 item, 2 questions)

Each question is answered by a score ranging from 1 to 4. For every item, a score is calculated according to answers, ranging from 0 to 100%. Mean scores of symptom items, functional items, and global health items are, then, obtained. We used an Arabic Tunisian dialectal version of QLQ-C30 which is widely used in Tunisia but still not validated \[[@B18]\].

2.4. Ethical Aspect {#sec2.4}
-------------------

In their inclusion, patients were asked to sign a written consent. The study protocol was discussed then accepted on November 9th 2018, by the ethics committee of Abderrahmen Mami (study protocol No 10/2018).

2.5. Statistical Analysis {#sec2.5}
-------------------------

We performed initially a descriptive statistical analysis to get frequencies, percentages, and mean sociodemographic parameters. Quantitative and objective assessment of sleep quality and quality of life was provided. Then, a comparative statistical analysis was conducted to identify correlations between mean scores of questionnaires or percentages (Student *t*-test or nonparametric tests) and between categorical parameters or frequencies (Qui square test).

3. Results {#sec3}
==========

We enrolled 107 patients during the study. Exclusion criteria were decisive in 53 cases. We kept 64 cases in the data collecting step. The mean age of our patients was 62.9 ± 8.18 years \[42-85\]. All patients were active smokers. Current smokers represented 48.4% of all patients. Most frequent past medical history were hypertension (23%) and COPD (21%), as mentioned in [Table 1](#tab1){ref-type="table"}. Eastern Cooperative Oncology Group Performance Status (ECOG PS) in the 1st consultation was less than 2 in 62.5% of all patients.

From the 1st consultation to the obtaining of histological confirmation, the mean delay was 40.6 days. Using the TNM 9th edition, 59.4% of patients were in stage IV of the disease ([Table 1](#tab1){ref-type="table"}). Four cycles of palliative chemotherapy was administered for all stage IV patients (59%). Curative concomitant chemoradiation was performed in 3 patients (4.7%). Chemotherapy associated to sequential radiotherapy was administered for 11 patients (17.2%). Curative chemotherapy without additional thoracic radiotherapy was administered for 12 patients (18.7%).

3.1. Sleep Quality--PSQI Questionnaire Analysis {#sec3.1}
-----------------------------------------------

Ten patients (15.6% of all patients) had poor sleep quality before chemotherapy. After chemotherapy, 29 patients (45.3%) had poor sleep quality ([Figure 1](#fig1){ref-type="fig"}). PSQI score of all patients went from 2.9 before treatment to 5.4 after treatment (*p* = 0.001). Most reported sleep disturbances were daytime sleepiness, prolonged sleep latency, and nocturnal arousals ([Table 2](#tab2){ref-type="table"}).

3.2. QLQ-C30 Questionnaire Analysis {#sec3.2}
-----------------------------------

High scored symptom items before chemotherapy onset were dyspnea (45.7%), anorexia (31.2%), and financial difficulties (42.7%). These findings showed the intensity of these complaints in our patients. Statistically significant rise after chemotherapy was noted in nausea and insomnia mean coefficients which reflected a worsening in these complaints ([Table 3](#tab3){ref-type="table"}). Mean coefficient of symptom items of all patients was 22% before chemotherapy onset, then became 25.4% after chemotherapy. The coefficient was significantly less in patients with PSQI score \< 5 and Performance Status score \< 2.

Performance item mean scores before and after chemotherapy were nearly similar, between 64.2% and 78.6%. Statistically significant decrease after chemotherapy was mentioned in "physical functioning" and "social functioning" ([Table 3](#tab3){ref-type="table"}). Mean coefficient of performance items of all patients was 71.3% before chemotherapy onset, then became 55.3% after chemotherapy. The coefficient was significantly better in patients with PSQI score \< 5 and Performance Status score \< 2. There was a statistically significant fall after chemotherapy in the mean coefficient of performance items of patients with preserved Performance Status score ([Table 4](#tab4){ref-type="table"}).

3.3. Predictive Factors of Poor Sleep Quality: ([Table 5](#tab5){ref-type="table"}) {#sec3.3}
-----------------------------------------------------------------------------------

Patients with good sleep quality and patients with bad sleep quality had a mean age of 62.9 years both. Clinical and demographic factors had no statistically significant effect on sleep quality in our patients (age, rural origin, histological subtype, disease stage, metastases, and their location).

Patients with poor sleep quality had a mean delay between their 1st consultation and histological confirmation significantly longer than patients with good sleep quality (47.2 days vs. 32.5 days; *p* = 0.05). As well, patients with poor sleep quality had a mean delay between histological confirmation and treatment onset significantly longer than patients with good sleep quality (28.1 days vs. 15.7 days; *p* = 0.0001).

Anxiodepressive mood was more frequently noted in poor sleep quality patients. Correlation between sleep quality and mood disturbances was statistically confirmed (*p* = 0.001). Factors related to treatment procedure (molecules of chemotherapy used on the first line, number of chemotherapy courses, in-patient or outpatient administration of treatment, and complication\'s occurring or severity) had no effect on sleep quality in our patients. Statistical multivariate analysis has shown an independent and significant correlation between sleep quality and therapeutic management delays ([Table 6](#tab6){ref-type="table"}).

4. Discussion {#sec4}
=============

Several key points distinguished our study and made its strength. The objective to identify predictive factors of sleep quality in cancer patients, its impact on quality of life, and its correlation with disease prognosis was reported by several studies \[[@B4], [@B6], [@B20], [@B21]\]. The correlation between quality of life and intensity of disease symptoms was previously established \[[@B20], [@B22]\]. Several studies also described a noticeable and sometimes unique correlation between quality of life and pain intensity. Strong recommendations derived from these studies to initiate early measurements to preserve quality of life and to control pain in cancer patients. Our methodology was to exclude patients with great pain levels, patients with poor general health, and patients on specific treatment interacting with sleep quality. That allowed us to select a coherent cohort of patients to evaluate the quality of life and its correlation with sleep quality independently from the influence of pain or general health \[[@B5]\]. Questionnaires are a validated tool to assess global health or symptom severity \[[@B12], [@B13]\]. Lack of objectivity for the PSQI questionnaire was noticed in several trials, especially in specific subgroups like cancer patients \[[@B23]\]. So, some authors used to combine the questionnaire to sleep diaries, actigraphy, or polysomnography \[[@B24]--[@B26]\]. There is a shortage of studies dedicated to analyse sleep quality in lung or chest cancer patients generally. However, sleep quality in many other types and localizations of cancer was assessed ([Table 7](#tab7){ref-type="table"}, [Table 8](#tab8){ref-type="table"}). Particular attention was granted to advanced stages, symptomatic patients, and survivor patients \[[@B20], [@B22], [@B27], [@B28]\]. These studies noted high PSQI scores. The blunt impact of the sociodemographic factors, the remarkable correlation between good sleep quality, and quality of life suggest an outstanding impact of the disease and the anxiodepressive reaction coming with it. A damaged "body image" could explain this fact, even with neither pain nor worsening of performance status. Poor quality of life in gynecologic cancer was widely described, even in operated patients ([Table 8](#tab8){ref-type="table"}).

After cancer treatment, the prevalence of poor sleep quality was usually between 54% and 79%. Results from the study of Ilhan et al. \[[@B29]\] illustrated the influence of therapeutic methods (surgery, chemotherapy, and radiation therapy) on sleep quality in endometrium cancer patients: the PSQI mean score moved from 4.6 before treatment to 8.1 after treatment and poor sleep quality prevalence rised from 28% to 79%.

The effect of therapeutic procedure in sleep quality of cancer patients was randomly noted in several studies ([Table 8](#tab8){ref-type="table"}). This fact could be explained by the heterogeneity in objectives or in the inclusion criteria of various trials. However, other findings must be underlined: Utility of questionnaires as assessment tools in cancer patients, high prevalence of sleep disturbances in cancer patients, and persistence of these troubles after specific treatment or even in survivor patients after a curative procedure. In lung cancer patients, sleep disturbances could be a "late-onset" phenomenon, noted mainly after chemotherapy. The relationship between quality of life and sleep disturbances does not make doubt. It seems to be strengthened when it is associated to mood disturbances. Also, anxiodepressive humor was described as a predictive factor of a declined quality of life \[[@B30]--[@B32]\]. Authors suggested to screen for poor quality of life and for mood disturbances, then to set up a psycho-oncological support program managed by the same structures of treatment. Such a nonpharmacological treatment could be effective in a cluster of poor sleeping patients.

5. Conclusions {#sec5}
==============

Interactions between sleep quality, sleep composition, immune system, homeostasis, and endocrine functions are mutual and complicated. So, sleep quality could have an indirect impact on psychological equilibrium, response to treatment disease progression, and prognosis. Preservation of sleep quality is a major palliative care increasingly mentioned in advanced cancer management. Nevertheless, sleep quality deterioration before and after chemotherapy of lung cancer wasn\'t studied. Assessment of sleep quality is usually forgotten by physicians. There is, till today, no clear recommendations for the treatment of insomnia. Our study described a statistically significant relation between sleep quality, quality of mood and quality of life before, and after chemotherapy in locally advanced NSCLC patients. Further prospective studies are still needed to establish evidence-based recommendations for the treatment of sleep disturbances in cancer patients.

A.1. Pittsburgh Sleep Quality Index (PSQI) Questionnaire in English Version. {#secA.1}
============================================================================

Arabic dialectal version is available from the corresponding author upon request.

A.2. PSQI Scoring {#secA.2}
=================

A.3. QLQ-C30 Questionnaire in English Version {#secA.3}
=============================================

A.4. QLQ-C30 Scoring {#secA.4}
====================
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###### 

Clinical characteristics of the lung cancer patients.

                                     Number   \%
  ---------------------------------- -------- --------
  Past medical history                        
   COPD                              21       32.8
   Pulmonary tuberculosis            10       15.6
   Hypertension                      23       35.9
   Diabetes mellitus                 9        14.1
   Gastroduodenal ulcer              10       15.6
   Benign prostatic hyperplasia      8        12.5
  Performance status (PS)                     
   0                                 17       26.6
   1                                 23       35.9
   2                                 22       34.4
   3                                 2        3.1
  Stage                                       
   IIIa                              4        6.3
   IIIb                              13       20.3
   IIIc                              9        14.1
   IVa                               10       15.6
   IVb                               14       21.9
   IVc                               14       21.9
  Delays (days)                      Mean     Median
   1^st^ X Ray--1^st^ consultation   18.5     17
   1^st^ consultation--diagnosis     40.6     32

###### 

Number and percent of sleep disturbances in poor sleep quality patients before and after chemotherapy.

  Sleep disturbances              Baseline (*n* = 10)   After chemotherapy (*n* = 29)   *p*                   
  ------------------------------- --------------------- ------------------------------- ------------- ------- ------
  Sleep hours \< 6 hours          2 patients            20%                             12 patients   41.4%   0.06
  Sleep hours \> 9 hours          4 patients            40%                             5 patients    17.2%   0.09
  Daytime sleepiness              7 patients            70%                             26 patients   89.6%   0.14
  Prolonged sleep latency         6 patients            60%                             20 patients   68.9%   0.33
  Delayed sleep phase disorder    0                     0                               1 patient     3.4%    0.18
  Advanced sleep phase disorder   1 patient             10%                             0             0       0.66
  Nocturnal arousals              10 patients           100%                            29 patients   100%    0.29

###### 

Outcome of the mean scores of QLQ-C30 items after chemotherapy.

                                           Before chemotherapy   After chemotherapy   *p*           
  ---------------------------------------- --------------------- -------------------- ------ ------ -------
  Items/symptoms                                                                                    
   Fatigue                                 32.3                  33.3                 34.9   33.3   0.61
   Nausea                                  3.5                   0                    15.4   0      0.04
   Pain                                    21.4                  0                    13     0      0.16
   Dyspnea                                 45.7                  33.3                 41.7   33.3   0.37
   Insomnia                                13                    0                    22.9   0      0.05
   Anorexia                                31.2                  0                    41.2   66.7   0.08
   Constipation                            10                    0                    11     0      0.43
   Diarrhea                                0                     0                    0.5    0      0.10
   Financial difficulties                  42.7                  33.3                 44.8   33.3   0.52
   Mean coefficient of symptom items       22                    20.7                 25.4   26.8   0.47
  Performance items                                                                                 
   Physical functioning                    64.2                  66.7                 12.7   13.3   0.001
   Role functioning                        76.6                  83.3                 73     83     0.47
   Emotional functioning                   71                    66.7                 65.7   66.7   0.21
   Cognitive functioning                   78.6                  83.3                 69     75     0.09
   Social functioning                      68                    72.7                 56     50     0.05
   Mean coefficient of performance items   71.3                  72.5                 55.3   58.5   0.09

###### 

Outcome of the mean coefficients before then after chemotherapy.

                                          Before chemotherapy   After chemotherapy   *p*                  
  --------------------------------------- --------------------- -------------------- ------ ------ ------ -----------
  Mean coefficient of symptom items                                                                       
  All patients (*n* = 64)                 22                    20.7                 25.4   26.8   0.31   
   Performance status                     0                     12.4                 11.1   17.5   12.3   0.14
  1                                       21.5                  22.2                 24.2   26.5   0.19   
  2                                       29.4                  30.8                 32.5   31.5   0.30   
  3                                       27.1                  27                   25.9   25.9   0.36   
   PSQI score                             \>5 (*n* = 29)        20.2                 18.5   18.6   19.1   0.55
  ≤5 (*n* = 35)                           31.8                  33.3                 33.5   32.1   0.34   
   BMI                                    ≤18 (*n* = 6)         29.9                 33.3   31.4   33     0.42
  \>18 (*n* = 58)                         20.7                  18.5                 24.7   26.5   0.18   
  TNM stage                               III (*n* = 26)        20                   19     18.5   20.3   0.39
  IV (*n* = 38)                           26                    26                   29.4   30.6   0.28   
  Mean coefficient of performance items                                                                   
  Tous les patients (*n* = 64)            71.3                  72.5                 55.3   58.5   0.08   
   PS                                     0                     79.1                 86.6   62.5   70.7   **0.038**
  1                                       76.8                  79                   60.3   65.4   0.13   
  2                                       62.7                  61.8                 46     45     0.11   
  3                                       37.5                  37.5                 40.9   40.9   0.23   
   PSQI score                             \>5 (*n* = 29)        50.5                 49     46     41.3   0.16
  ≤5 (*n* = 35)                           75.2                  78.7                 63     67     0.09   

###### 

Predictive factors of sleep quality--univariate statistical analysis.

                                                          Good sleepers           Poor sleepers        *p*      
  ------------------------------------------------------- ----------------------- -------------------- -------- -------
  Mean delays                                                                                                   
   1^st^ consultation -histological confirmation (days)   47.2                    32.5                 0.05     
   Histological confirmation--treatment onset (days)      28.1                    15.7                 0.0001   
  Disease-related parameters                                                                                    
   Stage                                                  III (%)                 41.4                 40       0.80
  IV (%)                                                  58.6                    60                            
   Histology                                              Adenocarcinoma (%)      58.6                 54.3     0.57
  Squamous cell carcinoma (%)                             27.6                    34.3                          
  Nonsmall cell carcinoma (%)                             13.8                    11.4                          
   Metastasis                                             Yes (%)                 58.6                 57.2     0.55
  No (%)                                                  41.4                    42.8                          
   Cerebral metastasis                                    Yes (%)                 17.2                 14.3     0.64
  No (%)                                                  82.8                    85.7                          
  Treatment-related parameters                                                                                  
   Chemotherapy course rate                               One day per cycle (%)   13.8                 17.2     0.49
  Two days per cycle (%)                                  86.2                    82.8                          
   Hospitalisation during course                          Inpatient (%)           34.5                 31.4     0.71
  Outpatient (%)                                          65.5                    68.6                          
   Grade IV complication                                  Yes (%)                 20.7                 37       0.09
  No (%)                                                  79.3                    63                            
  Sleep quality                                           Humor quality           Number of patients   \%       *p*
   PSQI \> 5                                              Normal                  3 patients           10.4%    0.001
  Depression                                              17 patients             58.6%                         
  Anxiety                                                 9 patients              31%                           
   PSQI ≤ 5                                               Normal                  28 patients          80%      0.001
  Depression                                              5 patients              14.3%                         
  Anxiety                                                 2 patients              5.7%                          

###### 

Predictive factors of sleep quality--multivariate statistical analysis.

  Variable                                  Univariate analysis   Multivariate analysis                 
  ----------------------------------------- --------------------- ----------------------- ------------- -------
  Mean delay to histological confirmation   0.05                  0.89                    0.83--0.96    0.004
  Mean delay to treatment onset             0.0001                1.37                    1.12--1.67    0.002
  Chemotherapy complications                0.09                  1.79                    0.46--6.95    0.39
  Depressive humor                          0.001                 1.60                    0.59--4.34    0.35
  Anxious humor                             0.001                 3.2                     0.68--15.09   0.14

###### 

Prevalence of insomnia in cancer patients.

  Author                                       Prevalence
  -------------------------------------------- ------------
  Delgado-Guay et al. \[[@B33]\]               85%
  Beck et al. \[[@B34]\]                       65%
  Silberfarb et al. \[[@B28]\] lung cancer     50.3%
  Silberfarb et al. \[[@B28]\] breast cancer   51%
  Mansano-Schlosser and Ceolim \[[@B35]\]      47.4%
  Our study: before chemotherapy               15.6%
  Our study: after chemotherapy                45.3%

###### 

Quality of life assessment and its correlation to sleep quality.

  Author                                Questionnaire                        Type of cancer                          Conclusion
  ------------------------------------- ------------------------------------ --------------------------------------- ----------------------------------------------------------------------------------------------------
  Kerner et al. \[[@B36]\]              QLQ-C30 and ESAS                     Breast or endometrium cancer            Enhancement of quality of life after CIM
  Fortmann et al. \[[@B37]\]            HRQOL                                All types of cancer/teenager patients   Correlation between quality of life, asthenia, and insomnia
  Beck et al. \[[@B34]\]                MOS PCS et MOS MCS                   Breast/stage I to IIIA                  Correlation between quality of life, physical, and mental health
  Trudel-Fitzgerald et al. \[[@B38]\]   Multidimensional fatigue inventory   Resected cancers of all types           Adjuvant treatment is correlated with more depression, anxiety, insomnia, asthenia, and pain
  Armbruster et al. \[[@B39]\]          SF36                                 Endometrium/early stages                Correlation between mental health and sleep quality
  Inhestern et al. \[[@B32]\]           SF8 et FAD-GF                        All cancer types survivors              Several items (social and familial support) are correlated to anxiety and depression
  Our study                             QLQ-C30 and PSQI                     Lung/advanced stages                    Several quality of life items (nausea, insomnia, physical performance) worsened after chemotherapy

CIM: Complementary integrative medicine ESAS: Edmonton Symptom Assessment Scale; FAD-GF: general functioning scale of the Family Assessment Device; HR-QOL: Health related-Quality of life; MOS MCS: Medical Outcomes Study Mental Component Score; MOS PCS: Medical Outcomes Study Physical Component Score; SF36: Short form.
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